268 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
3 Top Biotech Stocks For May https://www.fool.com/investing/2017/05/11/3-top-biotech-stocks-for-may.aspx?source=iedfolrf0000001 May 11, 2017 - These three biotechs could be stellar buys this month.
I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards https://www.fool.com/investing/2017/05/09/i-still-cant-believe-gilead-sciences-inc-spent-147.aspx?source=iedfolrf0000001 May 09, 2017 - Gilead's M&A targets may be limited because of its sizable shareholder rewards program.
Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat http://www.zacks.com/stock/news/259788/incyte-incy-q1-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-259788 May 08, 2017 - Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
Should You Get Rid of Incyte Corporation (INCY) Now? http://www.zacks.com/stock/news/257893/should-you-get-rid-of-incyte-corporation-incy-now?cid=CS-ZC--257893 Apr 26, 2017 - Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down http://www.zacks.com/stock/news/257738/lilly-lly-tops-q1-earnings-misses-sales-shares-down?cid=CS-ZC-FT-257738 Apr 25, 2017 - Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Read This Before You Buy Biotech Stocks https://www.fool.com/investing/2017/04/23/read-this-before-you-buy-biotech-stocks.aspx?source=iedfolrf0000001 Apr 23, 2017 - Looking to buy biotech stocks? Here are 7 important things to know.
Should Gilead Sciences Acquire NewLink Genetics? https://www.fool.com/investing/2017/04/21/gilead-sciences-should-acquire-newlink-genetics.aspx?source=iedfolrf0000001 Apr 21, 2017 - NewLink Genetics intriguing IDO-inhibitors could make it a target of Gilead Sciences.
This $26 Billion Company Is the Market's Most Overpriced Biotech Stock https://www.fool.com/investing/2017/04/20/this-26-billion-company-is-the-markets-most-overpr.aspx?source=iedfolrf0000001 Apr 20, 2017 - Nearly 90% of this biotech's sales could be at risk within the next two years.
Zacks Market Edge Highlights: Insulet, Incyte, Intuitive Surgical and Edwards Lifesciences http://www.zacks.com/stock/news/256903/zacks-market-edge-highlights-insulet-incyte-intuitive-surgical-and-edwards-lifesciences?cid=CS-ZC-FT-256903 Apr 19, 2017 - Zacks Market Edge Highlights: Insulet, Incyte, Intuitive Surgical and Edwards Lifesciences
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed http://www.zacks.com/stock/news/256797/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-on-oncomed?cid=CS-ZC-FT-256797 Apr 19, 2017 - Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

Pages: 1...18192021222324252627

<<<Page 23>